about
A Randomised Controlled Trial of Consent Procedures for the Use of Residual Tissues for Medical Research: Preferences of and Implications for Patients, Research and Clinical Practice.Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled studyThe role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer.The histophysiology and pathophysiology of the peritoneum.Incidence of lymph node metastases in clinical early-stage mucinous and seromucinous ovarian carcinoma: a retrospective cohort study.Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification.Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer.Improved outcomes due to changes in organization of care for patients with ovarian cancer in the Netherlands.Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.Evaluation of response to hormone therapy in patients with measurable adult granulosa cell tumors of the ovary.Multimodal surgical guidance towards the sentinel node in vulvar cancer.Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review.Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.Neoadjuvant chemotherapy or primary debulking surgery in FIGO IIIC and IV patients; results from a survey study in the Netherlands.Corrigendum to "Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre- versus post-operative risk stratification" [Eur J Cancer 78 (2017) 82-90].A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer.Human epididymis protein 4 immunostaining of malignant ascites differentiates cancer of Müllerian origin from gastrointestinal cancer.Treatment of ovarian metastases of colorectal and appendiceal carcinoma in the era of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.The use of SPECT/CT for anatomical mapping of lymphatic drainage in vulvar cancer: possible implications for the extent of inguinal lymph node dissection.Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.Association of allele-specific HLA expression and histopathologic progression of cervical carcinomaTumor-associated eosinophilic infiltrate of cervical cancer is indicative for a less effective immune responsePresence of an eosinophilic infiltrate in cervical squamous carcinoma results from a type 2 immune responseDevelopment and internal validation of a prognostic model for survival after debulking surgery for epithelial ovarian cancerDevelopment and internal validation of a prognostic model to predict recurrence free survival in patients with adult granulosa cell tumors of the ovaryPrimary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trialHyperthermic intraperitoneal chemotherapy for ovarian cancer: The heat is on
P50
Q35973982-56E76A39-E172-4661-9855-C0350000B840Q37501224-652C6BC6-C643-409B-81AB-6354C57BF03FQ38386340-E1102EDE-3BDD-41B7-BE0F-BAD484A4EE3EQ38790310-5B8A2891-3749-4A9B-AC9E-4FE55D7A70D4Q39176734-D68C29A9-7FBC-4758-8027-62D4024981C1Q40240102-75756328-3B14-4C28-9A93-4D66A83308BCQ40246622-F4193CEB-5023-47D1-B4B8-CEA13D75F7AFQ40793966-44E7A8E6-FCD6-417F-82D8-F22BFAA5FD80Q40889921-B111C201-AE49-4740-A9C6-2482AF9DC77EQ41526579-135A8A7D-D101-45DB-9DC0-DBF7AA9D5825Q45177844-CDE0713A-2F7A-4148-B9B6-355BD9487F86Q47823943-9E05B655-A250-4B22-9A8A-EF8896FEA550Q50000120-90614A3B-C27F-4452-825B-C34A3F59B2E2Q50420014-F1500762-AB17-4B88-BD68-2E92B19CC364Q50428820-42F85A2B-02A4-4817-98C1-D6394C1E2D08Q50801132-FD454DBC-EB51-4A2A-9C33-5100285D62CBQ51137244-C627E50C-F971-47BD-A622-86E903B02094Q51153713-DD576B89-BB09-45EA-8008-FE2F0D9AB83BQ52994146-DD74D3CB-B8D5-497B-BE01-8C0C128CC061Q53652467-F1FA9A5F-4EAA-4B8F-A101-8780057EFDF5Q71215874-DDCCC3CC-6C92-4CF6-B6D9-B3BE59C1F892Q71556917-665D3A57-33E2-4B2C-BA15-D8AF46251CE4Q78038901-EF16BC9B-95BE-4448-A5D6-DEB705B11FC5Q87505910-763CB2C7-883D-420F-A8A4-F6AD27A2C60FQ88194261-DF75E663-436B-4006-A7D5-09BF90A3B9FBQ90604579-59C17F5F-6C27-459E-AE46-8D1CD8F11F5BQ92847043-A4538A8A-3BC6-4656-A46F-BA5CE4E1BB65
P50
description
researcher
@en
wetenschapper
@nl
name
Willemien Johanna Van Driel
@en
van Driel WJ
@nl
type
label
Willemien Johanna Van Driel
@en
van Driel WJ
@nl
altLabel
van Driel WJ
@en
prefLabel
Willemien Johanna Van Driel
@en
van Driel WJ
@nl
P106
P31
P496
0000-0003-2246-1994